Pharvaris plans filings for HAE drug after pivotal trial win
Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.
Newsletters and Deep Dive digital magazine
Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.
Researchers in Türkiye have shown in a small clinical trial that laughter therapy can reduce breathing difficulties in COPD patients.
Novartis has suffered another pipeline blow, this time involving its highly anticipated neuromuscular disease therapy del-desiran.
The UK is starting to benefit from a "real partnership" between pharma and government, reversing years of diminishing investment, says the ABPI.
London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising €575m for "Europe's boldest innovators."
Editor's Picks
Newsletters and Deep Dive
digital magazine